FEMY

Femasys is a pre-commercial-scale women's-health device company whose entire equity value rests on FemBloc, a non-surgical permanent-birth-control candidate that has only just begun enrolling the final phase of its U.S. pivotal FINALE trial (March 2026). The commercialized portfolio (FemaSeed, FemVue, FemCerv, etc.) generated just $2.29M of FY2025 revenue — up 40.8% but from a trivial base — against an $18.6M net loss and negative operating margins of -767%. Five years of history show revenue crawling from $1.18M to $2.29M while cumulative losses drove the accumulated deficit to -$146M. At a $252M market cap this is 110x sales for a business that has never come close to covering its ~$18.7M annual cash burn.

The filing makes the funding risk explicit and imminent: management states existing cash and revenue — including ~$0.4M raised after year-end — fund operations only 'into the third quarter of 2026,' and that current resources are 'not sufficient to fund our operations through U.S. regulatory approval of FemBloc.' With just $9.27M of cash on the balance sheet at FY2025 and an $18.7M annual operating cash outflow, the company is at its stated runway limit right now (early July 2026) and must raise 'substantial additional capital' to complete FINALE and file a PMA. Shares outstanding already jumped 122.4% year-over-year, and the ATM/convertible/warrant financing history signals that the next raise will again be highly dilutive — likely at or below the current price given the cash-cliff leverage financiers hold.